arrow_back Trending Legislation
Share share

Boosting US Drug Production, Reducing Reliance on China

This resolution suggests that government rules and taxes have made it hard for US companies to make medicines here, leading to reliance on countries like China. It calls for changes to make it easier to produce drugs in the US, aiming to improve availability and national security.
Key points
Calls for reducing taxes and rules that make it difficult to manufacture medicines in the US.
Aims to decrease reliance on foreign countries, particularly China, for essential drugs and ingredients.
Suggests promoting free market policies to strengthen US drug production and counter unfair trade practices.
Recommends improving how the government tracks where drug ingredients come from.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.
Print number: HRES 280
Sponsor: Rep. Jackson, Ronny [R-TX-13]
Process start date: 2021-03-26
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-04-17
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Boosting US Drug Production, Reducing Reliance on China

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HRES 280.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-03-26.

What are the main provisions?

Key points include:

  • Calls for reducing taxes and rules that make it difficult to manufacture medicines in the US.
  • Aims to decrease reliance on foreign countries, particularly China, for essential drugs and ingredients.
  • Suggests promoting free market policies to strengthen US drug production and counter unfair trade practices.
  • Recommends improving how the government tracks where drug ingredients come from.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Jackson, Ronny [R-TX-13].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Analysis and Potential Impact of HRES 280

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Economy Security Health